Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orsini, F
Right arrow Articles by Polack, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orsini, F
Right arrow Articles by Polack, B
Haematologica, Vol 90, Issue 9, 1288-1290
Copyright © 2005 by Ferrata Storti Foundation

Letter

Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors

F Orsini, C Rotschild, P Beurrier, A Faradji, J Goudemand, and B Polack

We retrospectively evaluated the efficacy of immune tolerance induction (ITI) in a homogenous cohort of eight patients with constitutive severe hemophilia A with high-responding factor VIII (FVIII) inhibitors using Facteur VIII-LFB/Factane, a highly purified FVIII concentrate containing von Willebrand factor (VWF).


This article has been cited by other articles:


Home page
 ASH Education BookHome page
D. Lillicrap
The Role of Immunomodulation in the Management of Factor VIII Inhibitors
Hematology, January 1, 2006; 2006(1): 421 - 425.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.